Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Equity Average: 2011-2025

Historic Equity Average for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to $167.4 million.

  • Abeona Therapeutics' Equity Average rose 181.32% to $167.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.4 million, marking a year-over-year increase of 181.32%. This contributed to the annual value of $29.4 million for FY2024, which is 41.53% up from last year.
  • Per Abeona Therapeutics' latest filing, its Equity Average stood at $167.4 million for Q3 2025, which was up 63.34% from $102.5 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Equity Average peaked at $167.4 million during Q3 2025, and registered a low of $3.0 million during Q1 2024.
  • Over the past 3 years, Abeona Therapeutics' median Equity Average value was $32.2 million (recorded in 2024), while the average stood at $47.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 86.93% in 2024, then skyrocketed by 1,336.96% in 2025.
  • Abeona Therapeutics' Equity Average (Quarterly) stood at $61.1 million in 2021, then tumbled by 67.93% to $19.6 million in 2022, then decreased by 5.87% to $18.4 million in 2023, then soared by 143.61% to $44.9 million in 2024, then skyrocketed by 181.32% to $167.4 million in 2025.
  • Its Equity Average stands at $167.4 million for Q3 2025, versus $102.5 million for Q2 2025 and $42.7 million for Q1 2025.